At Vaccines Europe our thoughts are with all those affected by the outbreak of the coronavirus (COVID-19). Vaccines Europe, part of the European Federation of Pharmaceutical Industries and Associations (EFPIA), stands in support with the global community and the World Health Organization (WHO) to contain the COVID-19 pandemic.
While governments contend with implementing appropriate public health measures and health systems are treating unprecedented numbers of patients requiring intensive care, our industry is focused on three key areas:
The COVID-19 pandemic is the public health challenge of our time, which requires a concerted effort and new solutions to be found together. Vaccines Europe, as a representative of innovative research & development vaccine manufacturers, is honoured to be a part of the R&D ecosystem that responds n a spirit of partnership. We participate in an unprecedent exchange of information and dialogue with other stakeholders on how to address this pandemic.
Europe’s collaborative research community has responded to global health crises before. Through efforts such as the Innovative Medicines Initiative and other public-private partnerships1, we advanced new Ebola vaccine candidates, and diagnostics, and developed new identification and compliance tools. Collaborating in this way has the potential to accelerate development of resources to tackle this pandemic. It enables networks of centres of excellence that can deliver real impact and create a preparedness infrastructure which can be mobilized for future outbreaks.
Our members are committed to ensure that when new vaccines are approved they are available and affordable. See all our commitments here.